Clearmind Advances CMND-100 into Phase IIa Dosing for Alcohol Use Disorder
CMND sits 31% above its 52-week low of $1.43.
Summary
Clearmind Medicine has begun Phase IIa dosing of CMND-100 in patients with alcohol use disorder, with six patients enrolled across two Israeli sites — one-third of the planned Part C cohort.
Key Events · Product Development and Regulatory · CMND
-
Phase IIa Initiation
CMND-100 has entered Phase IIa, the multiple-dose treatment stage of the Phase I/IIa trial for alcohol use disorder, with six patients enrolled to date.
-
Enrollment Progress
Three patients enrolled at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem, representing one-third of the planned Part C cohort.
-
First Patient Dosing
This marks the first time CMND-100 is being administered to individuals with moderate-to-severe AUD, following successful completion of the healthy-volunteer safety portion.
-
DSMB Support
An independent Data and Safety Monitoring Board previously reviewed Part A data and recommended advancing to subsequent study parts, supporting continued clinical evaluation.
Analysis · CMND · Life Sciences
Clearmind has advanced its lead drug candidate CMND-100 into Phase IIa, the multiple-dose efficacy stage of its Phase I/IIa trial for alcohol use disorder. Six patients are enrolled across two Israeli medical centers, representing one-third of the planned Part C cohort. This is the first time the drug is being tested in patients with moderate-to-severe AUD, moving beyond the healthy-volunteer safety data reported in prior months. For a micro-cap company with a going-concern warning and a market cap under $3 million, clinical progress is the primary driver of any remaining equity value.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.43 to $524.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.